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Abstract
Objective
To estimate HIV incidence and highlight the characteristics of persons at greatest risk of
HIV in the Ukraine capital, Kiev.
Method
Residual samples from newly-diagnosed persons attending the Kiev City AIDS Centre were
tested for evidence of recent HIV infection using an avidity assay. Questions on possible
risk factors for HIV acquisition and testing history were introduced. All persons (16yrs) pre-
senting for an HIV test April’13–March’14 were included. Rates per 100,000 population
were calculated using region-specific denominators.
Results
During the study period 6370 individuals tested for HIV. Of the 467 individuals newly-diag-
nosed with HIV, 21 had insufficient samples for LAg testing. Of the remaining 446, 39
(8.7%) were classified as recent with an avidity index <1.5ODn, 10 were reclassified as
long-standing as their viral load was <1000 copies/mL, resulting in 29 (6.5%) recent HIV
infections. The only independent predictor for a recent infection was probable route of expo-
sure, with MSMmore likely to present with a recent infection compared with heterosexual
contact [Odds Ratio 8.86; 95%CI 2.65–29.60]. We estimated HIV incidence at 21.5 per
100,000 population, corresponding to 466 new infections. Using population estimates for
MSM and PWID, incidence was estimated to be between 2289.6 and 6868.7/100,000
MSM, and 350.4 for PWID.
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Conclusion
A high proportion of persons newly-infected remain undiagnosed, with MSM disproportion-
ally affected with one in four newly-HIV-diagnosed and one in three recently-HIV-infected.
Our findings should be used for targeted public health interventions and health promotion.
Introduction
Prevalence and incidence rates are important measures of disease. Determining the number of
persons who have been recently-infected with HIV enables current transmission patterns to be
ascertained, highlighting populations at greatest risk and guiding prevention and intervention
strategies. However, given the long latency period which characterises HIV disease, these mea-
sures are not easily estimated in practice.
Serological tests identifying biological markers of recent infection are fast becoming an
alternative method to cohort studies and mathematical models. These serological tests use key
components of the antibody response to the virus, including antibody concentration, response,
reaction or proportion, isotype and avidity [1–6]. Supplemented by clinical evidence of a recent
or established infection, this process has been termed the Recent Infection Testing Algorithm
(RITA). Unlike cohort studies, the RITA methodology requires a sample of serum to be taken
at a single point in time; at HIV diagnosis, without the need for follow-up.
Identifying and classifying recent HIV infections in Ukraine is a priority as the country has
one of the highest HIV diagnosis rates in Europe at 37.1 per 100,000 population [7]. Further-
more ‘hidden epidemics’ make appropriate targeted public health interventions problematic
and, with a shift in HIV risk from persons who inject drugs (PWID) to sexual transmission,
particularly heterosexual contact, there is a need to identify and characterise recent HIV infec-
tions to better inform policy.
We sought to estimate HIV incidence in the Ukraine capital, Kiev, and to highlight the char-
acteristics of persons at greatest risk of HIV using published methodologies [8,9]. Findings
from this study on testing and positivity rates have previously been published [10]. Here we
examine factors related to recent infection and provide HIV incidence estimates using data
from the same cohort.
Methods
In April 2013 we introduced a new methodology for data collection for persons newly-present-
ing for an HIV test at the main testing facilities in the City of Kiev. These testing facilities con-
sisted of four infectious disease clinics for HIV, collectively known as the Kiev City AIDS
Centre. Details of this methodology have been described previously [10]. In Brief, at the time of
testing we collected information on residence, risk factors for acquiring HIV, reason for test
and testing history through a short anonymous questionnaire to be completed by the clinic
attendee using a handheld electronic tablet.
All adults (16years) presenting or referred for an HIV test at the Kiev City AIDS Centre,
between 1st April 2013 and 31st March 2014 were included. Persons testing as part of antenatal
or blood donation screening were excluded, as different methodologies for estimating HIV
incidence are required for these populations, given that population sizes for these groups are
known.
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Data Management
Data were captured by a remote secure server and downloaded for analysis. Records were de-
duplicated using year of birth, sex, and identification number, with any discrepancies queried
and resolved with the laboratory. The identification number was used to match the person’s
data with their HIV test result. All records with incomplete information (year of birth, sex and
date of diagnosis), or with a previous HIV positive test and, therefore, not a new diagnosis,
were removed. Data are presented for persons aged 16 years and over by age quartiles.
Probable route of exposure was determined based on the attendee’s answer to the following
questions: ever injected drugs, ever had sex with a person of the opposite sex, ever had sex with
a person of the same sex, ever paid for sex, and ever been paid for sex. Persons with more than
one reported risk factor were classified by the following hierarchical order: PWID, men who
have sex with men (MSM), then sex between men and women. Additional information was
available on sexual behaviour (ever paid for sex, ever been paid for sex, or partner of a PWID).
Information on the reason for test was grouped into the following three categories: clinical
indication (persons presenting with symptoms), high risk population (those regarded to engage
in high risk behaviour i.e. injecting drugs, contact of a known HIV-positive person, those diag-
nosed with a sexually transmitted infection, those who experienced an occupational HIV risk,
and those reporting sex with multiple partners), and general screening (before surgical inter-
ventions, recruitment into the army, prisoners and persons requiring an HIV test due to regu-
lations or policy, e.g. for employment or visa procurement). Persons with more than one
reported reason for test were classified by the following hierarchical order: general screening,
clinical indication, then high risk population.
Laboratory Methods
All samples were tested for HIV at the HIV reference laboratory at the Kiev City AIDS Centre,
Ukraine using an ELISA test. Residual samples from persons with a confirmed new diagnosis
were tested for evidence of recent infection using the limiting antigen (LAg) avidity EIA assay
[11–13].
The LAg avidity assay differentiates recent from long-standing infections using the strength
of the bond between the viral protein (antigen) and the HIV-specific antibody. A low avidity
represents a recent infection. The normalised optical density is estimated by dividing the opti-
cal density of the specimen by the mean optical density of the calibrator, with recent infection
being assigned to samples with an optical density of<1.5, and a mean duration of recent infec-
tion being equal to 130 days (95% CI: 118–142) [13]. The initial test requires samples to be
screened, with samples with an ODn2.0 being tested in triplicate for confirmation.
As evaluations of the LAg avidity assay indicated that the assay performed poorly on speci-
mens with a low or undetectable viral load and from persons on cART [14], samples with viral
load<1000 copies/mL were reclassified as longstanding.
Incidence Estimates
HIV incidence was estimated using the stratified extrapolation method initially proposed by
Karon et al (18) and modified by Prejean et al [8]. Briefly, this modified method uses the
observed number of recent infections, and the probability a person will present for an HIV test
and be classified as recent using RITA, to estimate the true number of infections within the
population during the period of interest. The observed number of recent infections equates
to the number of HIV-positive individuals testing for HIV and being assigned recent by the
LAg assay, after reclassifying samples with viral load<1000 copies/mL as longstanding. To
establish the true number of recent infections (Tr) the observed number (Or) is divided by the
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probability of testing and being classified as recent (P).
Tr ¼ Or=P
The estimation of this probability is derived for repeat testers and ﬁrst-time testers sepa-
rately. For repeat testers, i.e. with previous HIV negative test result, Pi is estimated as the proba-
bility of being classiﬁed as recent (Sw(t)) at the time of their test since infection, over the
distribution of possible infection time, which is assumed uniform over the interval between the
last negative and ﬁrst positive test dates. For each individual we consider the time in months
between their last negative test and ﬁrst positive test dates. The probability of testing and being
classiﬁed as recent for that individual (Pi) is the weighted sum of each possible date of serocon-
version within that interval. The overall probability of testing and being classiﬁed as recent (P)
is then the average of each person’s Pi.
Pi ¼
1
Ti
Z Ti
0
SwðtÞdt
The assumption for ﬁrst-time testers is that the testing rate is constant during the interval
from infection to AIDS (deﬁned as a CD4 cell count<200 cells/mm3), where the rate, the esti-
mated mean time from infection to ﬁrst test (β) can be made based on the proportion of per-
sons diagnosed with a simultaneous HIV and AIDS diagnosis referred to as q; αA being the
shape parameter of the incubation period from infection to an AIDS diagnosis, and βA being
the scale parameter of the incubation period.
b ¼ ½bA½q1=aA  1
P is estimated by the weighted sum of the probability that a person tests within the assay’s
recency period, and the probability that the test is performed before AIDS develops.
Z 1
0
SwðtÞSAðtÞ
1
b
et=bdt
Where data were missing on probable route of exposure, RITA classiﬁcation or testing history,
we used a 20-fold multiple imputation procedure on the observed data and 95% conﬁdence
intervals were calculated using bootstrap methodologies, where the original data were resam-
pled 1000 times to create 1000 datasets from which the probabilities for testing and being clas-
siﬁed as recent were estimated to give the upper and lower estimates.
Region-specific denominators for Kiev City were based on data collected through the gov-
ernment census [15]. Rates were calculated by dividing the number of tests, diagnoses or esti-
mated number of recent infections for the calendar year by the population denominator and
multiplied by 100,000. Incidence rates per year were calculated for Kiev City overall, and by age
and sex using population estimates as denominators. We used published estimates of subpopu-
lations at risk of HIV to derive subgroup estimates. The first is from the AIDS Alliance which
estimated that, in Kiev City in 2012, there were 23,400 PWID and 9,400 MSM, the latter being
0.9% of the male population [16]. The second is from the European MSM internet survey
(EMIS) which estimates that MSM represented 0.3% of the male population, with the ‘best’
estimate being 0.7% [17].
For comparison with published literature we also present incidence estimates by the original
method by Karon et al [9], where the probability of testing and being classified as recent (P), is
the product of the probability of testing within a year of infection (P1), the probability of a con-
firmed positive sample having a RITA result (P2) and the probability the result is recent within
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a year of infection (Pw). P is estimated as follows.
P ¼ P 1  P2  PW
Statistical analyses were performed using STATA version 12 (STATA Corp, College Station,
TX, USA).
Ethics statement
The study was part of CASCADE within EuroCoord (www.EuroCoord.net) funded by the
European Union Framework Programme VII. Ethics approval was given by the ethics commit-
tee of the Institute of Epidemiology and Infectious Diseases, Academy of Medical Sciences of
Ukraine, Kiev, Ukraine and the ethics committee of University College London (UCL).
Results
Population characteristics
During the 12-month period April 2013 –March 2014, 6402 persons were tested for HIV.
Thirty-two were excluded as follows: 7 records were missing year of birth, sex or identification
number, and 25 persons were already known to be HIV positive.
The remaining 6370 tests (3425 in men and 2945 in women) gave a crude test rate of 293.2
per 100,000 population (aged16 years). HIV test results could not be linked for 353 speci-
mens. Of the remaining 6017 tests with a result, 467 (7.8%) were HIV positive, equivalent to a
diagnosis rate of 21.5 per 100,000. The completion rate for questionnaires was 99.4% with 39
persons not providing any further information. The median age among those newly-diagnosed
was 32 years [Inter Quartile Range: 28–36], and HIV prevalence among those testing was high-
est among persons aged 31–35 years, males, PWID and MSM (Table 1). Over half (56%) of per-
sons newly-diagnosed tested due to clinical indicators, 35% due to high risk behaviour, and
8.7% through general public screening. Of note, the majority of persons tested through screen-
ing reported more than one reason for test, of whom 33 (83%) also reported high risk
behaviour.
Recent HIV infection
Of the 467 individuals newly-diagnosed with HIV, 21 had insufficient samples for LAg testing.
Of the remaining 446, 39 (8.7%) were classified as recent with an avidity index<1.5 ODn. Of
those, 10 had a viral load<1000 copies/mL and were, therefore, not considered recent. There-
fore, of 446 individuals tested, 29 (6.5%) were recent HIV infections; 6.6% among repeat testers
and 6.5% among first-time testers.
For the 29 recently-infected individuals, median age was 30 years [IQR: 24–34], with men
accounting for two thirds of recent infections. Table 1 shows the distribution of persons classi-
fied as recently-infected, with a higher proportion of recent infections among younger adults,
men, MSM, and those resident in Kiev City.
We found that the only independent predictor for being recently-infected was probable
route of exposure, with MSMmore likely to present with a recent infection compared with per-
sons reporting heterosexual contact [Odds Ratio 8.86; 95% CI 2.65–29.60] (Table 2). Where
exposure category was reported, MSM accounted for 50% (14/28) of recent infections with het-
erosexual men and women each accounting for 18% (n = 10). The majority of MSM classified
as recent fell into the age group 26–30 years (57%; 8/14) and tested due to high risk behaviour
(71%; 10/14). PWID represented 14% (n = 4) of recent infections, of whom the majority (75%)
were male.
HIV Incidence in Kiev City
PLOS ONE | DOI:10.1371/journal.pone.0157179 June 8, 2016 5 / 13
HIV incidence estimates
We estimated HIV incidence at 21.5 per 100,000 population during the period April 2013 –
March 2014, corresponding to 466 new infections.
Although a higher proportion of recent infections were among 16–25 year olds, incidence
estimates were highest among those aged 26–30 years and 31–35 years (both 72.5 per 100,000).
Men had the highest incidence estimates at 34.3 compared with 10.2 for women. Using popula-
tion estimates for MSM and PWID, incidence was estimated to be between 2289.6 and 6868.7
per 100,000 MSM, and 350.4 for PWID (Table 3).
Incidence estimates using the Karon et almethodology results in an incidence estimate of
25.9 per 100,000 with 562 new infections.
Table 1. Characteristics of persons newly diagnosed with HIV and the proportion identified as recently infected using the LAg Avidity EIA, Kiev
City, Ukraine: April 2013 –March 2014.
Newly
Diagnosed
Samples available for LAg test Recent
Classiﬁcation
N = 467 % N = 446 N = 29 %
Age (years)
16–25 64 4.6 61 8 13
26–30 120 7.1 115 10 8.7
31–35 154 11.2 144 8 5.6
36 129 8.3 126 3 2.4
Sex
Male 303 9.4 288 23 8.0
Female 164 5.9 158 6 3.8
Residence
Kiev (city) 391 7.2 373 28 7.5
Kiev area (small town) 53 13.8 51 1 2.0
Kiev area (village) 10 9.3 10 0 0
Another area of Ukraine 7 16.3 6 0 0
Not Reported 6 6
Probable route of exposure
Persons who inject drugs: Male 137 17.1 130 3 2.3
Persons who inject drugs: Female 41 21.5 40 1 2.5
Men who have sex with men 46 24.1 43 14 33
Heterosexual contact: Male 114 5.1 109 5 4.6
Heterosexual contact: Female 122 4.7 117 5 4.3
Not Reported 7 7 1
Testing History
Repeat tester 84 6.2 76 5 6.6
First-time tester 349 7.8 338 22 6.5
Not reported 34 32 2
Reason for test
Clinical Indicators 257 11.0 248 20 8.1
High risk Behaviour 163 5.5 154 8 5.2
General Public Screening 40 6.0 37 1 2.7
Not Reported 7 7
doi:10.1371/journal.pone.0157179.t001
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Table 2. Factors association with testing recent according to the LAg assay in Kiev City, Ukraine: April 2013 –March 2014
Univariate odds ratio for testing recent
(95% conﬁdence interval) pvalue
Multivariate odds ratio for testing
recent¥ (95% conﬁdence interval)
pvalue
Age Years (per 10 year increase) 0.48 (0.25,0.94) 0.023 0.65 (0.32,1.33) 0.217
Sex
Male 1 0.133 1 0.928
Female 0.51 (0.20,1.29) 0.96 (0.28,3.17)
Residence
Kiev City 1 0.039 1 0.141
Outside Kiev City 0.19 (0.03,1.45) 0.27 (0.03,2.14)
Probable route of exposure
Persons who inject drugs 0.61 (0.18,2.01) 0.59 (0.16,2.10)
Men who have sex with men 11.05 (4.39,27.82) 8.86 (2.65,29.60)
Heterosexual contact 1 <0.001 1 <0.001
Testing History
Repeat tester 1 0.960 1 0.256
First-time tester 1.03 (0.38,2.80) 0.76 (0.25,2.30)
Reason for test
Clinical Indicators 1 0.236 1 0.621
High risk behaviour 0.57 (0.23,1.38) 0.47 (0.18,1.25)
General public screening 0.31 (0.04,2.39) 0.46 (0.06,3.80)
¥ Adjusting for all factors in table.
doi:10.1371/journal.pone.0157179.t002
Table 3. Incidence estimates for Kiev City, Ukraine, April 2013 –March 2014, by subpopulations.
Population (16) Number newly infected
with HIV (95% CI) ††
HIV incidence rate (95% CI) †
Total 2,172,448 466 396–567 21.5 18.2–26.1
Age (years)
16–25 484,839 121 102–148 25.0 21.0–30.5
26–30 212,340 154 130–188 72.5 61.2–88.5
31–35 177,968 129 109–159 72.5 61.2–89.3
36 1,297,301 59 50–71 4.5 3.9–5.5
Sex
Male 990,412 340 288–414 34.3 29.1–41.8
Female 1,182,301 120 102–147 10.2 8.6–12.4
Probable route of exposure
Persons who inject drugs 23,400¥ 82 70–1000 350.4 299.1–427.4
Men who have sex with men 2970‡ 204 172–251 6868.7 5791.2–8451.2
8910‡‡ 2289.6 1930.4–2817.1
Heterosexual contact 6¼ 159 135–195 6¼ 6¼
† per 100,000 population
†† Adjusted for Viral load
6¼ Population level data not available
¥ Based on MARP estimates by AIDS Alliance [18]
‡ Derived from the European MSM internet survey (EMIS), where an estimated 0.3% of the male population are MSM [17]
‡‡ Based on MARP estimates by AIDS Alliance, where an estimated 0.9% of the male population are MSM [18].
Source: State Statistics Service of Ukraine. Ukraine Census [15].
doi:10.1371/journal.pone.0157179.t003
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Discussion
For the first time we present direct estimates of HIV incidence for Kiev City for the period
April 2013 –March 2014, with 21.5 per 100,000 population, equating to an estimated 466 new
HIV infections during that period. These findings are similar to those reported for the USA
using the same methodology, where the overall incidence estimate was 19.0.
It is difficult to place our estimate within the global context, due to differences in methodol-
ogies used. The extrapolation process for identifying the true number of recent infections in a
population has been used in the USA, France, and the Italian region of Lazio, with HIV inci-
dence estimates of 19.0, 17.0, and 19.9, respectively [8,19,20]}. However, estimates for France
and Lazio were based on the original methodology by Karon et al. Limitations to the original
methodology discussed by Prejean et al [8] suggest that the incidence estimates of 17.0 and
19.9 per 100,000 for France and Lazio, respectively, are an overestimation. This has been dem-
onstrated by the USA where both methodologies were used with incidence decreasing from
22.8 using the original methodology to 19.0 per 100,000 [8,21]. Our incidence estimates using
the Karon methodology were 25.9 per 100,000 compared with 21.5. Both the distribution of
new diagnoses and recent infections demonstrated disproportionate HIV infection among
MSM [10], with one in four MSM newly-diagnosed and one in three recently-infected. The
estimated number of new infections among MSM was 185, representing the majority of the
206 estimated for the overall population. Using published estimates [16,17] to define the popu-
lation at risk within Ukraine, incidence estimates for MSM ranged between 2076.3 new infec-
tions per 100,000 MSM based on 0.9% of the male population being MSM [16], and 6229.0 if
this proportion was 0.3% [17]. These alarmingly high incidence rates, compared with those for
the overall population, are similar to rates given for France [20] (1006 among MSM vs. 17
among the total population) and Los Angeles county [22] (493 vs. 23 respectively). However,
these estimates are based on the original methodology by Karon et al, which Prejean et al
highlighted results in an overestimation of incidence.
The work builds on our previous findings indicating that MSM and PWID are dispropor-
tionately affected by HIV; we reported that diagnosis rates for these two groups were as high as
24.1% and 17.9%, respectively compared with 4.9% among persons reporting heterosexual con-
tact. Our data also indicated a bridging between high risk individuals and their heterosexual
partners with an estimated 1 in 6 heterosexual women reporting contact with a PWID [10].
For the first time detailed information on HIV risk behaviour was available, allowing for tar-
geted awareness, prevention and testing among at-risk populations. This disproportionate dis-
tribution of HIV among MSM indicates that onward transmission in this group is high, and
highlights the need for tailored prevention and intervention strategies [10]. Furthermore, the
lack of exposure information across Ukraine means that the scale of the epidemic among these
high risk groups is unknown. Work in the UK on the likely sources of onward transmission in
this subpopulation suggests that high incidence among MSM is driven by condomless sex and
would be even higher without the introduction of antiretroviral therapy [23]. ART coverage in
Ukraine is one of the lowest internationally (22–28%) [24] and EMIS indicated that MSM in
Ukraine are not being reached by prevention efforts, and have minimal understanding of HIV
and its prevention [17].
Like MSM, PWID are also a hard to reach population, with underlying tension between law
enforcements and those involved in public health [25]. Diagnosis figures for Ukraine [7] show
sexual contact between men and women exceed that of injecting drug use becoming the leading
route of infection. However, there is evidence of onward transmission within this group sug-
gesting that PWID are still an important subpopulation. UNAIDS indicates that harm reduc-
tion programmes are available in all regions of Ukraine, but reach only a third of those at risk,
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and<10% are accessing treatment [26]. Work modelling the effectiveness of medication-assis-
ted treatment for opioid dependence (MAT), ART and syringe exchange programmes (SEP)
among PWID, estimated that as high as 40% of HIV among PWID could have been avoided
[27].
There are several limitations worthy of discussion. Firstly, the data required to estimate the
probability of testing and being classified as recent are prone to error. For repeat testers this is
based on the time between the last negative test and an individual’s first positive test which is,
therefore, reliant on these data being reported accurately. In Kiev City, as is likely in most sur-
veillance systems, the availability of these data is based on self-reporting. Underestimating the
time interval between an individual’s negative and positive test will increase the probability of
testing and being classified as recent. A higher probability would result in an underestimation
of the true number of recent infections. If this interval is overestimated this would result in a
lower probability and an overestimated incidence rate. For first-time testers, the proportion of
the population diagnosed late is used to estimate the time between infection and presenting for
a test. As availability of these data are limited for Kiev City, we used data collected from patient
notes for the first quarter of 2013 and estimated the proportion among all new diagnoses rather
than for first-time testers specifically. It is difficult to know how representative the assumptions
used within the model among those seeking testing are relative to those who do not. However,
the model assumes that all HIV infections will be diagnosed eventually. Secondly, population
data, particularly for MSM, within Kiev City was estimated using published literature, based on
the work of AIDS Alliance [16] and the European MSM internet survey [17]. There are uncer-
tainties within these estimates, and we present the results based on the minimum and maxi-
mum estimates. Further work is needed to establish the likely numbers at risk. Thirdly, data
from Kiev City may well not be generalizable to the rest of Ukraine. For a better understanding
of the epidemic in other regions, it would be beneficial to consider implementation of our data
collection methods across Ukraine. Fourthly, the proportion of persons diagnosed late was not
available by subpopulations and, therefore, incidence will have been under or over-estimated
for subgroups as the probability of being diagnosed recent for the overall population was
applied to subgroup estimates. Finally, we were unable to assess the possible effect of previous
ART use on our estimates. It is unlikely, however, that any newly-diagnosed individuals had
been on ART given the low ART coverage rate among those in need of it in the Ukraine. In any
case, we reclassified all those with a low VL as non-recent, which will have reduced any possible
effect of ART.
This study speaks to the need for targeted testing. With only 29 persons diagnosed among
the estimated 466 new infections, a high number of persons newly-infected remain undiag-
nosed, who may well be participating in high-risk behaviour increasing the risk of onward
transmission. The transmission rate among undiagnosed persons has been estimated to be 3.5
times higher than among those diagnosed [28], as those undiagnosed are likely to have a higher
viral load and, therefore, at higher risk of onward transmission [29–34]. Furthermore, this
knowledge base will better enable targeted public health action, health promotion work, laying
a foundation to facilitate local and national guidelines to be developed, and to support work
being conducted by government and non-government organisations.
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